<div id="readability-page-1"><h3>Claim 70% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>An update from China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) is now available. China Resources Pharmaceutical Group Limited has called its first extraordinary general meeting of 2026 for 6 February in Beijing, where shareholders will vote on approving a new Sales Framework Agreement for 2026–2028, including the associated transaction caps and authorization for directors to execute related documents. The meeting will also consider a special resolution to adopt a new Articles of Association to replace the existing constitution, signaling a potential update to the company’s corporate governance framework, and the outcomes—decided by poll—may shape its operational arrangements and internal rules going forward. The most recent analyst rating on (HK:3320) stock is a Hold with a HK$5.00 price target. To see the full list of analyst forecasts on China Resources Pharmaceutical Group Ltd. stock, see the HK:3320 Stock Forecast page. More about China Resources Pharmaceutical Group Ltd. China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated company listed on the Stock Exchange of Hong Kong, operating in the pharmaceutical industry. The group focuses on the production, distribution and sale of pharmaceutical products and related healthcare services in mainland China, leveraging a broad network and scale within the domestic healthcare market. YTD Price Performance: 2.02% Average Trading Volume: 12,761,952 Technical Sentiment Signal: Sell Current Market Cap: HK$28.52B </div>

China Resources Pharmaceutical Group Ltd. has scheduled its first extraordinary general meeting for February 6, 2026, in Beijing. Shareholders will vote on a new Sales Framework Agreement for 2026-2028 and a special resolution to adopt new Articles of Association, potentially updating the company's governance framework. The current analyst rating for the stock (HK:3320) is a Hold with a price target of HK$5.00. The company operates in the pharmaceutical sector in mainland China, with a market cap of HK$28.52B and a year-to-date price performance of 2.02%.

Tip Ranks

CHINARES PHARMA

Penghua SSE STAR Biology and Medicine ETF

Guotai SSE STAR Brand Name Drug ETF

China Merchants CSI Biotechnology Theme ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI 300 Health Care ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Ping An CSI Medicine and Medical Device Innovation ETF

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund CSI Biotechnology Theme ETF

Guotai CSI Bio-medicine ETF

Yinhua CSI Research Sector 100 ETF

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund Hang Seng SCHK Innovative Drug ETF

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

Yinhua CSI Innovative Drugs Industry ETF

Tianhong CNI BIOMEDICINE ETF

China Universal 800 Health Care ETF

Founder Fubon CSI Medicine and Medical Device Innovation ETF

Penghua CSI HK Connect Health Care Composite ETF

China Resources Pharmaceutical Calls 2026 EGM to Approve Sales Framework and New Articles